

9869SG3840-seq1-000001
SEQUENCE LISTING

<110> Agency for Science, Technology and Research
<120> Self-Assembling Ultrashort Aliphatic Cyclic Peptides for
Biomedical Applications
<130> A32687WO
<150> SG10201502526Y
<151> 2015-03-31
<160> 52
<170> PatentIn version 3.5
<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> (X)a of cyclic peptide
<400> 1
Leu Ile Val Ala Gly
1 5

<210> 2
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> (X)a of cyclic peptide
<400> 2
Ile Leu Val Ala Gly
1 5

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> (X)a of cyclic peptide
<400> 3
Leu Ile Val Ala Ala
1 5

<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> (X)a of cyclic peptide
<400> 4

Leu Ala Val Ala Gly
1 5

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a of cyclic peptide
<400> 5

Ile Val Ala Gly
1

<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a of cyclic peptide
<400> 6

Leu Val Ala Gly
1

<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a of cyclic peptide
<400> 7

Ile Leu Val Ala
1

<210> 8
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a of cyclic peptide
<400> 8

Leu Ile Val Ala
1

<210> 9
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a of cyclic peptide

<400> 9

Leu Ile Val Gly
1

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a of cyclic peptide

<400> 10

Ala Ile Val Ala Gly
1 5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a of cyclic peptide

<400> 11

Gly Ile Val Ala Gly
1 5

<210> 12

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a of cyclic peptide

<400> 12

Val Ile Val Ala Gly
1 5

<210> 13

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a of cyclic peptide

<400> 13

Ala Leu Val Ala Gly
1 5

<210> 14

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a of cyclic peptide

<400> 14

Gly Leu Val Ala Gly
1 5

<210> 15

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a of cyclic peptide

<400> 15

Val Leu Val Ala Gly
1 5

<210> 16

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a-(Y)b of cyclic peptide

<400> 16

Leu Ile Val Ala Gly Lys
1 5

<210> 17

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a-(Y)b of cyclic peptide

<400> 17

Ile Leu Val Ala Gly Lys
1 5

<210> 18

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> (X)a-(Y)b of cyclic peptide

<400> 18

Leu Ile Val Ala Ala Lys
1 5

<210> 19

<211> 6

<212> PRT

<213> Artificial Sequence

<220>
<223> (X)a-(Y)b of cyclic peptide

<400> 19

Leu Ala Val Ala Gly Lys
1 5

<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a-(Y)b of cyclic peptide

<400> 20

Ala Ile Val Ala Gly Lys
1 5

<210> 21
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a-(Y)b of cyclic peptide

<400> 21

Leu Ile Val Ala Gly Ser
1 5

<210> 22
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a-(Y)b of cyclic peptide

<400> 22

Ile Leu Val Ala Gly Ser
1 5

<210> 23
<211> 6
<212> PRT
<213> Artificial sequence

<220>
<223> (X)a-(Y)b of cyclic peptide

<400> 23

Leu Ile Val Ala Ala Ser
1 5

<210> 24
<211> 6

<212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 24

Leu Ala Val Ala Gly Ser
 1 5

<210> 25
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 25

Ala Ile Val Ala Gly Ser
 1 5

<210> 26
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 26

Leu Ile Val Ala Gly Asp
 1 5

<210> 27
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 27

Ile Leu Val Ala Gly Asp
 1 5

<210> 28
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 28

Leu Ile Val Ala Ala Asp
 1 5

<210> 29
 <211> 6
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 29
 Leu Ala Val Ala Gly Asp
 1 5

<210> 30
 <211> 6
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 30
 Ala Ile Val Ala Gly Asp
 1 5

<210> 31
 <211> 6
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 31
 Leu Ile Val Ala Gly Glu
 1 5

<210> 32
 <211> 6
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 32
 Leu Ile Val Ala Gly Thr
 1 5

<210> 33
 <211> 6
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 33
 Ile Leu Val Ala Gly Thr
 1 5

<210> 34
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 34

Ala Ile Val Ala Gly Thr
 1 5

<210> 35
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 35

Ala Ile Val Ala Gly Lys
 1 5

<210> 36
 <211> 5
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 36

Leu Ile Val Ala Asp
 1 5

<210> 37
 <211> 5
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 37

Leu Ile Val Gly Asp
 1 5

<210> 38
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 38

Ile Val Ala Asp
1

<210> 39
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide
 <400> 39

Ile Val Ala Lys
1

<210> 40
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide wherein Xaa = ornithine (Orn)
 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be any naturally occurring amino acid
 <400> 40

Leu Ile Val Ala Gly Xaa
1 5

<210> 41
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide wherein Xaa = ornithine (Orn)
 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be any naturally occurring amino acid
 <400> 41

Ile Leu Val Ala Gly Xaa
1 5

<210> 42
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> (X)a-(Y)b of cyclic peptide wherein Xaa = ornithine (Orn)
 <220>

<221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be any naturally occurring amino acid
 <400> 42

Ala Ile Val Ala Gly Xaa
 1 5

<210> 43
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> (X)a-(Y)b of cyclic peptide wherein Xaa = 2,4-diaminobutyric acid
 (Dab)

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be any naturally occurring amino acid
 <400> 43

Leu Ile Val Ala Gly Xaa
 1 5

<210> 44
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> (X)a-(Y)b of cyclic peptide wherein Xaa = 2,4-diaminobutyric acid
 (Dab)

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be any naturally occurring amino acid
 <400> 44

Ile Leu Val Ala Gly Xaa
 1 5

<210> 45
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> (X)a-(Y)b of cyclic peptide wherein Xaa = 2,4-diaminobutyric acid
 (Dab)

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be any naturally occurring amino acid
 <400> 45

Ala Ile Val Ala Gly Xaa
1 5

<210> 46
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a-(Y)b of cyclic peptide wherein Xaa = 2,3-diaminopropionic acid (Dap)

<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa can be any naturally occurring amino acid

<400> 46

Leu Ile Val Ala Gly Xaa
1 5

<210> 47
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a-(Y)b of cyclic peptide wherein Xaa = 2,3-diaminopropionic acid (Dap)

<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa can be any naturally occurring amino acid

<400> 47

Ile Leu Val Ala Gly Xaa
1 5

<210> 48
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> (X)a-(Y)b of cyclic peptide wherein Xaa = 2,3-diaminopropionic acid (Dap)

<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa can be any naturally occurring amino acid

<400> 48

Ala Ile Val Ala Gly Xaa
1 5

<210> 49
 <211> 7
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> (X)a-(Y)b of cyclic peptide

 <400> 49
 Leu Ile Val Ala Gly Lys Lys
 1 5

<210> 50
 <211> 7
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> (X)a-(Y)b of cyclic peptide

 <400> 50
 Leu Ile Val Ala Gly Ser Ser
 1 5

<210> 51
 <211> 7
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> (X)a-(Y)b of cyclic peptide

 <400> 51
 Leu Ile Val Ala Gly Asp Asp
 1 5

<210> 52
 <211> 7
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> (X)a-(Y)b of cyclic peptide

 <400> 52
 Leu Ile Val Ala Gly Glu Glu
 1 5